Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
134.00
-1.95 (-1.43%)
At close: Nov 18, 2026, 4:00 PM EST
133.76
-0.24 (-0.18%)
Pre-market: Nov 19, 2026, 8:22 AM EST
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $259.69M in the quarter ending September 30, 2026, with 51.87% growth. This brings the company's total for the last twelve months to $865.27M, up 54.16% year-over-year. In the year 2025, Axsome Therapeutics had annual revenue of $638.50M with 65.55% growth. That makes Axsome Therapeutics the 8,334th largest company in the world by revenue and 1,892nd in the United States.
Revenue (ttm)
$865.27M
Revenue Growth
+54.16%
P/S Ratio
8.15
Revenue / Employee
$622,495
Employees
1,390
Market Cap
7.05B
Revenue by Geography
- United States 628.62M 98.5%
- Outside of The United States 9.88M 1.5%
Fiscal year ended Dec 31, 2025 See the full Axsome Therapeutics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 638.50M | 252.80M | 65.55% |
| Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
| Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
| Dec 31, 2022 | 50.04M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Corcept Therapeutics | 963.65M |
| Twist Bioscience | 459.43M |
| Arrowhead Pharmaceuticals | 450.82M |
| ImmunityBio | 182.57M |
| Cytokinetics | 113.29M |
| CG Oncology | 6.17M |
| ABIVAX Société Anonyme | 5.33M |
AXSM News
- 1 hour ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 days ago - Axsome Therapeutics Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 6 days ago - Axsome Therapeutics price target lowered to $223 from $249 at Morgan Stanley - TheFly
- 9 days ago - Axsome Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 15 days ago - Axsome Therapeutics price target lowered to $272 from $284 at Mizuho - TheFly
- 15 days ago - Axsome Therapeutics price target lowered to $245 from $267 at Deutsche Bank - TheFly
- 16 days ago - Axsome Therapeutics price target raised to $249 from $247 at Morgan Stanley - TheFly
- 16 days ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire